Zydus Lifesciences Limited’s (formerly known as Cadila Healthcare Limited) subsidiary Zydus Worldwide DMCC has received tentative approval from the United States Food and Drug Administration (USFDA) to market Valbenazine Capsules USP 40 mg, 60 mg, and 80 mg (USRLD: Ingrezza®) & Roflumilast Tablets USP, 250 mcg (USRLD: Daliresp®).
- Read more about Zydus gets two approval from USFDA
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/zydus-receives-approval-from-the-usfda-for-valbenazine-capsules
No comments:
Post a Comment